Quick Takeaways Retatrutide is a triple-receptor agonist (GLP-1, GIP, glucagon) delivering superior monotherapy weight loss at 2428.7% over 4868 weeks Cagrilintide targets amylin receptors for satiety and gastric emptying, achieving 10.8% weight loss in 26 weeks as a monotherapy Retatrutide provides broader metabolic benefits, including dramatic improvements in HbA1c, blood pressure, waist circumference, insulin sensitivity, and liver fat normalization No head-to-head trials exist yet, but the mechanistic and clinical data strongly favor Retatrutide for total body recomposition Retatrutide vs Cagrilintide: Side-by-Side Comparison What Makes Retatrutide Different Retatrutide isnt just another GLP-1 receptor agonist
The other activates three
BPC-157 vs Other Peptides How does BPC-157 stack up against other regenerative peptides
When handling, use aseptic techniques to prevent contamination
We makeBPC-157availableto individuals and to institutions wishing to conduct further research on the substance
Whether FDA accepts those recommendations, and how it words any subsequent rule, will set the pattern for the five peptides due for review before the end of February 2027
